Landscapes / Targets
tyrosine kinase
116 drugs act on tyrosine kinase, in 393 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs116
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Kinase inhibitor |
Sanofi · Public SNY |
Approved | 25 Nov 2026soonPhase 3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 25 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia (wAIHA) and 8 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 27 Nov 2026soonPhase 1 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 27 Nov 2026 · Phase 1 trial completes | ||||
| Also tested for | Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) and 2 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Roche · Public ROG.SW |
Approved | 30 Nov 2026soonPhase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Cancer and 2 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Roche · Public ROG.SW |
Approved | 30 Nov 2026soonPhase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Solid Tumors and 3 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved in China | Nov 2026soonPhase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Advanced Hepatocellular Carcinoma (HCC), Metastatic Colorectal Cancer and 4 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | Nov 2026soonPhase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Chronic Lymphocytic Leukemia, CLL and 18 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved | 11 Dec 2026soonPhase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 11 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis and 2 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved in China | 24 Dec 2026Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 24 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Neurofibromatosis 1, Plexiform Neurofibromas and 2 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
CSPC · Public 1093.HK |
Approved in China | 25 Dec 2026Phase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 25 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | C-Met Exon 14 Mutation, Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression and 3 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 30 Dec 2026Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis and 3 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Pfizer · Public PFE |
Approved | 31 Dec 2026Phase 3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Advanced Malignancies, NSCLC and 16 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | Dec 2026Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Biliary Tract Cancer, Advanced or Metastatic Solid Tumor and 16 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved in China | 31 Dec 2026Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 31 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Non-Small-Cell Lung Cancer, Non-small Cell Lung Cancer and 1 more | ||||
| Open drug page | |||||
Cytomegalovirus pUL97 kinase inhibitor |
Approved | 18 Jan 2027Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 18 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Cytomegalovirus (CMV) | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Novartis · Public NVS |
Approved | 2 Feb 2027Phase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 2 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Melanoma, EGFR-mutant Non-small Cell Lung Cancer and 30 more | ||||
| Open drug page | |||||
Acalabrutinibnot checked |
Kinase inhibitor |
AstraZeneca · Public AZN |
Approved | 15 Feb 2027Phase 3 trial completes | |
| How it works | Blocks a kinase | ||||
| Next date | 15 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL) and 20 more | ||||
| Open drug page | |||||
Kinase Inhibitor; mTOR inhibitor immunosuppressant |
Novartis · Public NVS |
Approved | 26 Feb 2027Phase 3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 26 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Tuberous Sclerosis Complex | ||||
| Open drug page | |||||
Kinase inhibitor |
Merck & Co. +1 · Public MRK |
Approved | 22 Mar 2027Phase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 22 Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Carcinoma, Renal Cell, Renal Cell Carcinoma and 14 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved in the EU | 31 Mar 2027Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 31 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Melanoma | ||||
| Open drug page | |||||
Raf kinase inhibitor |
Approved in the EU | 31 Mar 2027Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 31 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Melanoma | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 96 of 116 drugs. The other 20 are marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026